Estrella Immunopharma, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Estrella Immunopharma, Inc. annual/quarterly Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2021 to Q3 2023.
  • Estrella Immunopharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending September 30, 2023 was $20M.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $12.8M.
  • Estrella Immunopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$35.6M, a 177% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $20M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-20
Q1 2023 $187K Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-18
Q1 2021 $42.9K Jan 6, 2021 Mar 31, 2021 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.